This week we’re joined by Rhys Cohen, Australian Cannabis Consultant, and Editor at Large of Cannabiz Australia.
In this episode, Rhys gives us a high level overview of cannabis down-under, including its changing public perceptions, patient access to medical products, and progress towards decriminalisation.
→ View full show notes, summary, and access resources here:
Rhys has delivered consulting projects to most of Australia’s leading cannabis companies and has worked extensively with the Lambert Initiative for Cannabinoid Therapeutics at the University of Sydney. He has presented at numerous industry events including ACannabis (2021); Prohibition Partners Live (2020); and New Frontier Global Cannabis Town Hall (2020). His industry analysis has been cited by Deloitte Access Economics; the Victorian Department of Economic Development, Jobs, Transport and Resources; the Commonwealth Office of Drug Control; the Commonwealth Senate Standing Committee on Community Affairs; and the International Journal of Drug Policy. Rhys has also appeared in ABC News; The Australian Financial Review, The Age; The Sydney Morning Herald; and MJBiz Daily. He is the editor-at-large for Australia’s leading industry news platform Cannabiz. And he sits on the Advisory Board of market intelligence and research company FreshLeaf Analytics.
‘[In Australia] the existence of the medical properties of cannabis are not disputed by anyone’ 06:31
Once it becomes easy and cheap enough here is no reason why other people who aren’t medicinal cannabis patients could start accepting cannabis on prescription. That combined with the public change in attitudes towards cannabis legalisation more generally… I think we’re approaching a point in which we’re going to start having the initial conversation about cannabis law reform’ 32:00
Join Rhys on LinkedIn: https://www.linkedin.com/in/rhyscohen/
Rhys’s Website: https://www.rhyscohen.com/
Join Rhys onTwitter: https://twitter.com/rhyscohen
Cannabis Australia: https://www.cannabiz.com.au/